Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) Shares Outstanding (Weighted Average) (2020 - 2025)

Pulse Biosciences has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $67.3 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $67.3 million for Q3 2025, up 10.15% from a year ago — trailing twelve months through Sep 2025 was $67.3 million (up 10.15% YoY), and the annual figure for FY2024 was $3.0 million, down 93.97%.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $67.3 million at Pulse Biosciences, up from $208406.0 in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for PLSE hit a ceiling of $67.3 million in Q3 2025 and a floor of $208406.0 in Q2 2025.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $29.7 million (2022), compared with a mean of $30.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 4026.9% in 2021 and later plummeted 99.64% in 2025.
  • Pulse Biosciences' Shares Outstanding (Weighted Average) stood at $288490.0 in 2021, then soared by 2431.75% to $7.3 million in 2022, then skyrocketed by 580.97% to $49.7 million in 2023, then plummeted by 93.97% to $3.0 million in 2024, then surged by 2144.37% to $67.3 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $67.3 million (Q3 2025), $208406.0 (Q2 2025), and $3.0 million (Q4 2024) per Business Quant data.